TELA Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.70next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly19.1M
OviTex Unit Volume Growth Quarterly1,600.0%Target: Double-digit growth
Gross Margin Quarterly6,600.0%Target: 67-68%
Watch Items
- U.S. Product Mix HeadwindsTrigger: Further shift to smaller-sized units reducing average selling price (ASP)Action: Accelerate commercial push of larger-sized OviTex PRS and robotic/laparoscopic configurations to offset ASP declines.
- Cash Burn and Liquidity RunwayTrigger: Cash balance falling below $25 millionAction: Evaluate additional draws on the Perceptive Advisors credit facility or implement further operating expense controls.
Research as of 19 Jun 2026